TY - JOUR
T1 - Detection of undiagnosed diabetes and other hyperglycemia states
T2 - The atherosclerosis risk in communities study
AU - Schmidt, Maria Ines
AU - Duncan, Bruce B.
AU - Vigo, Alvaro
AU - Pankow, James
AU - Ballantyne, Christie M.
AU - Couper, David
AU - Brancati, Frederick
AU - Folsom, Aaron R.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - OBJECTIVE - To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose tolerance test (OGTT) for detection of diabetes or other hyperglycemic states - impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention. RESEARCH DESIGN AND METHODS - We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive. RESULTS - Screening based on the IFG cut point (≥6.1 mmol/l), followed by a clinical detection rule for those below this value, detected 86.3%)% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5.6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases. CONCLUSIONS - Screening strategies based on FPG, complemented by clinical detection rules and/or an OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
AB - OBJECTIVE - To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose tolerance test (OGTT) for detection of diabetes or other hyperglycemic states - impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention. RESEARCH DESIGN AND METHODS - We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive. RESULTS - Screening based on the IFG cut point (≥6.1 mmol/l), followed by a clinical detection rule for those below this value, detected 86.3%)% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5.6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases. CONCLUSIONS - Screening strategies based on FPG, complemented by clinical detection rules and/or an OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
UR - http://www.scopus.com/inward/record.url?scp=0042168852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042168852&partnerID=8YFLogxK
U2 - 10.2337/diacare.26.5.1338
DO - 10.2337/diacare.26.5.1338
M3 - Article
C2 - 12716785
AN - SCOPUS:0042168852
SN - 0149-5992
VL - 26
SP - 1338
EP - 1343
JO - Diabetes care
JF - Diabetes care
IS - 5
ER -